A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
NCT ID: NCT04508907
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
200 participants
INTERVENTIONAL
2020-09-10
2026-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Pre-emptive Treatment Arm
Single arm study were all recipients of HCV viremic organs will receive combination therapy.
Mavyret
Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mavyret
Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to accept and consent for accepting hepatitis C positive graft
Exclusion Criteria
* Concomitant infection with HIV or Chronic hepatitis B
* Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection
* Pregnancy (Pregnant patients do not undergo solid organ transplants)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bashar Aqel
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bashar A Aqel
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Phoenix, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-001964
Identifier Type: -
Identifier Source: org_study_id